Ikena Oncology
Ikena Oncology Logo
About Ikena Oncology
Ikena Oncology Inc is a biotechnology company focused on developing novel cancer therapies that target key signaling pathways involved in cancer growth, spread, and resistance. Its lead program, IK-930, is an oral, TEAD1-selective small molecule inhibitor of the Hippo pathway. The company is also developing IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology aims to address unmet needs in oncology through differentiated, biomarker-driven targeted therapies.
Address
645 Summer Street, Suite 101
Boston, 02210
United States
Year founded
2016
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
